Kim Tsuchimoto
Directeur Financier/CFO chez MONOPAR THERAPEUTICS INC.
Fortune : 31 645 $ au 30/04/2024
Profil
Kim R.
Tsuchimoto is the founder of Mercaptor Discoveries, Inc. (founded in 2016) where they held the title of Chief Financial Officer from 2017 to 2019.
Ms. Tsuchimoto's current job(s) include being the CFO, Secretary, Treasurer & Director at Monopar Therapeutics, Inc. since 2015.
They are also a Director at Thiogenesis Therapeutics, Inc. and an Independent Director at Thiogenesis Therapeutics Corp.
since 2022.
Ms. Tsuchimoto's former job(s) include being the Controller at International Microcomputer Software, Inc. from 2005 to 2006, Controller & Assistant Vice President at SpatiaLight, Inc. in 2005, Vice President-Treasurer & Controller at BioMarin Pharmaceutical, Inc. from 1997 to 2005, Chief Financial Officer, Secretary & Treasurer at Raptor Pharmaceutical, Inc., Treasurer, Vice President & Controller at Glyko, Inc. from 1997 to 2005, VP-Financial Planning & Analysis, Internal Control at Raptor Pharmaceuticals Corp.
from 2006 to 2015, and Vice President-Finance at Horizon Pharmaceutical LLC in 2012.
Ms. Tsuchimoto's education history includes an undergraduate degree from San Francisco State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MONOPAR THERAPEUTICS INC
0,29% | 31/03/2024 | 50 470 ( 0,29% ) | 31 645 $ | 30/04/2024 |
| 08/12/2022 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Kim Tsuchimoto
| Sociétés | Poste | Début |
|---|---|---|
| MONOPAR THERAPEUTICS INC. | Directeur Financier/CFO | 01/06/2015 |
| THIOGENESIS THERAPEUTICS, CORP. | Directeur/Membre du Conseil | 31/03/2022 |
Anciens postes connus de Kim Tsuchimoto
| Sociétés | Poste | Fin |
|---|---|---|
Mercaptor Discoveries, Inc.
 Mercaptor Discoveries, Inc. Pharmaceuticals: MajorHealth Technology Mercaptor Discoveries, Inc. is a pharmaceutical company based in Novato, CA. The private company develops chemistry that gives CNS drugs potency without the commonly found toxicity. The company's approach flows from their discovery of chemistry existing within areas of the brain suffering neuropathology. Applying their discovery to neurology has illuminated a path forward for neurotherapeutics, delivering drugs capable of mounting a dynamic response to brain damage and dysfunction. Mercaptor Discoveries is a platform company with preclinical programs in neurology. The company's founding scientists discovered injury-activated molecules, called captons™ while at Raptor Pharmaceuticals, which they co-founded in 2006 and grew into a commercial company. Captons have reproducible proof-of-concept and efficacy as neuroprotectants and have the potential to prevent the progression of traumatic brain injury (TBI) and neurodegenerative diseases such as Alzheimer's disease, ALS, epilepsy, Parkinson's disease, MS, and stroke. The company was founded in 2016 by Todd Zankel, Sara Isbell, and Kim R. Tsuchimoto. Sara Isbell has been the CEO since 2016. | Fondateur | 01/08/2019 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Directeur Financier/CFO | 01/05/2015 |
International Microcomputer Software, Inc.
 International Microcomputer Software, Inc. Packaged SoftwareTechnology Services International Microcomputer Software, Inc. develops software for productivity, utility, and digital image categories | Comptroller/Controller/Auditor | 01/03/2006 |
| SPATIALIGHT, INC. | Comptroller/Controller/Auditor | 23/08/2005 |
| BIOMARIN PHARMACEUTICAL INC. | Comptroller/Controller/Auditor | 01/06/2005 |
Formation de Kim Tsuchimoto
| San Francisco State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| THIOGENESIS THERAPEUTICS, CORP. | Finance |
| Entreprise privées | 8 |
|---|---|
International Microcomputer Software, Inc.
International Microcomputer Software, Inc. Packaged SoftwareTechnology Services International Microcomputer Software, Inc. develops software for productivity, utility, and digital image categories | Technology Services |
SpatiaLight, Inc.
 SpatiaLight, Inc. Electronics/AppliancesConsumer Durables SpatiaLight, Inc. filed bankruptcy on February 21, 2008. The company previously engaged in the business of manufacturing high-resolution LCoS microdisplays. Its customers are original equipment manufacturers engaged in the business of manufacturing high definition television. The company was founded in 1989 and is headquartered in Novato, CA. | Consumer Durables |
| Raptor Pharmaceutical, Inc. | Health Technology |
Glyko, Inc.
 Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
| Monopar Therapeutics, Inc. | |
Mercaptor Discoveries, Inc.
Mercaptor Discoveries, Inc. Pharmaceuticals: MajorHealth Technology Mercaptor Discoveries, Inc. is a pharmaceutical company based in Novato, CA. The private company develops chemistry that gives CNS drugs potency without the commonly found toxicity. The company's approach flows from their discovery of chemistry existing within areas of the brain suffering neuropathology. Applying their discovery to neurology has illuminated a path forward for neurotherapeutics, delivering drugs capable of mounting a dynamic response to brain damage and dysfunction. Mercaptor Discoveries is a platform company with preclinical programs in neurology. The company's founding scientists discovered injury-activated molecules, called captons™ while at Raptor Pharmaceuticals, which they co-founded in 2006 and grew into a commercial company. Captons have reproducible proof-of-concept and efficacy as neuroprotectants and have the potential to prevent the progression of traumatic brain injury (TBI) and neurodegenerative diseases such as Alzheimer's disease, ALS, epilepsy, Parkinson's disease, MS, and stroke. The company was founded in 2016 by Todd Zankel, Sara Isbell, and Kim R. Tsuchimoto. Sara Isbell has been the CEO since 2016. | Health Technology |
